Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0003 0.00 (0.00%)
As of 08/13/2026
Compare

SMFL vs. GNCA, PXMD, ARDS, GNCAQ, and SCPS

Should you buy Smart for Life stock or one of its competitors? Smart for Life's main competitors and comparable companies include Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), Genocea Biosciences (GNCAQ), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Smart for Life compare to Genocea Biosciences?

Smart for Life (NASDAQ:SMFL) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Genocea Biosciences Neutral

Smart for Life has higher revenue and earnings than Genocea Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Smart for Life has a beta of 15.1, meaning that its stock price is 1,410% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Summary

Smart for Life beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Smart for Life compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, indicating that its share price is 1,410% more volatile than the broader market.

Smart for Life's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Smart for Life N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Smart for Life Neutral

PaxMedica has higher earnings, but lower revenue than Smart for Life. PaxMedica is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Smart for Life beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Smart for Life compare to Aridis Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Smart for Life has a beta of 15.1, indicating that its stock price is 1,410% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.62, indicating that its stock price is 4,862% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Aridis Pharmaceuticals Neutral

Summary

Smart for Life beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Genocea Biosciences?

Smart for Life (NASDAQ:SMFL) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Genocea Biosciences N/A N/A N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Genocea Biosciences Neutral

Genocea Biosciences has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Smart for Life has a beta of 15.1, suggesting that its stock price is 1,410% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market.

Summary

Smart for Life beats Genocea Biosciences on 5 of the 5 factors compared between the two stocks.

How does Smart for Life compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

28.4% of Smart for Life shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, indicating that its stock price is 1,410% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Smart for Life N/A N/A N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Smart for Life Neutral

Scopus BioPharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SMFL vs. The Competition

Export
MetricSmart for LifePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2K$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / Sales0.00743.50592.5787.62
Price / CashN/A66.4570.4850.90
Price / Book0.0011.6012.916.24
Net Income-$22.68M$2.77B$3.45B$347.60M
7 Day PerformanceN/A0.17%1.12%1.07%
1 Month PerformanceN/A0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat		N/A-95.2%$2K$11.11MN/A110
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$5KN/A0.0030
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel